NRx Pharmaceuticals (NRXP) FDA announcement summary

Introduction and purpose

• FDA approval call outlined commercial launch plans, U.S. sterile-drug supply needs, preservative-free formulation, and potential expansion beyond ketamine.

• First approved product marks a transition from development-stage to commercial operations.

Details of approval or decision

• FDA approved the ANDA ahead of its November 10, 2026 goal date; review took less than 14 months versus a stated 35.6-month ANDA average.

• The Luer lock blow-fill-seal vial was reviewed as a drug-device combination, including scrutiny by FDA’s device center.

Impact on industry and stakeholders

• Ketamine injection had been on the shortage list since February 2018; all six manufacturers had at least one presentation back-ordered, intermittent, or allocated in October 2026, and some had discontinued production.

• Nephron’s U.S. production in West Columbia, South Carolina, uses high-volume blow-fill-seal technology; nearly 60% of sterile injectables used in the U.S. are manufactured overseas.

• The U.S. ketamine market was described as approaching $400 million in 2027 at a $5-per-vial MAC price; demand grew 17% in 2025.

• Hospital buyers prioritized reliable supply and simpler, safer preparation; intended uses include anesthesia and pain control, including labor and delivery.